Open AccessGalcanezumab (Emgality)
Author(s) -
Reimbursement Team
Publication year - 2022
Publication title -
canadian journal of health technologies
Language(s) - English
Resource type - Journals
ISSN - 2563-6596
DOI - 10.51731/cjht.2022.236
Subject(s) - migraine , headaches , drug class , medicine , drug , intensive care medicine , psychiatry , family medicine
CADTH recommends that Emgality should be reimbursed by public drug plans for the prevention of migraine if certain conditions are met.
Emgality should only be covered to prevent migraine attacks in adult patients who have tried at least 2 other types of oral preventive medications.
Emgality should only be reimbursed if the patient is being cared for by a physician who has experience managing migraine headaches. Emgality will only be reimbursed for 6 months at a time. Emgality should not be more than the least costly drug of the same class used to prevent migraine.